Alan P. Venook, MD of University of California San Francisco discusses the primary and secondary endpoints of the RECOURSE trial for which TAS-102 was approved at ASCO GI 2016
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content